When Cigna or Aetna tells you a PA request for oncology testing is "managed by eviCore," you're entering a different process — different portal, different clinical criteria, different appeal pathway. It trips up practices that assume it's the same as going through the payer directly.
Disclaimer: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk.
What eviCore Is and Who Uses It
eviCore healthcare (now part of Evernorth, Cigna's health services subsidiary) is a specialty benefits management company that payers contract with to conduct clinical reviews for high-cost services. Rather than building internal clinical review capacity for oncology imaging, radiation oncology, and molecular testing, payers outsource the review to eviCore, which uses its own set of evidence-based clinical guidelines.
As of 2026, eviCore manages oncology-related PA reviews for: Cigna commercial and Medicare Advantage plans, Aetna commercial plans in select markets, multiple Blue Cross Blue Shield affiliates, and UnitedHealthcare Medicare Advantage plans for certain testing categories. The specific services they manage differ by payer — one payer might route only oncology imaging through eviCore while routing molecular testing through their own clinical team. Verify which services are eviCore-managed for each payer by checking the payer's PA list or calling provider services.
How to Submit Through the eviCore Portal
Go to evicore.com, select your payer from the dropdown, and log in with your provider credentials. Each payer routes to its own submission queue within the same platform.
You'll enter: the member ID, plan information, ordering provider NPI, CPT code(s), ICD-10 diagnosis codes, and clinical information. The clinical questionnaire is dynamic — it changes based on the CPT code and the diagnosis you enter. Answer each question specifically. eviCore reviewers flag vague answers. "Patient has advanced cancer" will not satisfy a question asking for specific staging and prior treatment history.
For molecular testing (NGS panels, biomarker testing, comprehensive genomic profiling), eviCore's clinical pathways require: tumor type confirmed with pathology, disease stage (specific — not "metastatic" alone, but which metastatic sites and whether the disease is newly diagnosed or recurrent), prior systemic treatments with response data, and the specific clinical question the test is intended to answer.
Save your case number the moment you submit. eviCore doesn't send confirmation emails reliably. The case number is how you track status and initiate peer-to-peer requests.
eviCore's Oncology Clinical Pathways
eviCore uses its own clinical pathways for oncology that draw on NCCN guidelines, ASCO recommendations, and the medical literature. Their pathways are published (look for "Clinical Guidelines" on the eviCore website), but they're updated frequently and can lag behind or differ from NCCN in specific areas.
For comprehensive genomic profiling of solid tumors, eviCore's criteria generally align with NCD 90.2 (CMS's national coverage determination for NGS in cancer). They require: advanced cancer (recurrent, relapsed, refractory, metastatic, or stage 3/4), use in a Medicare-certified lab, and that the test is being used to guide patient management. If you're submitting for an NGS panel on a stage 2 solid tumor, you're fighting an uphill battle with eviCore — their criteria typically require advanced disease.
For liquid biopsy and circulating tumor DNA testing, eviCore's coverage is more selective. They generally require a specific clinical rationale for why a tissue-based test isn't feasible (patient not biopsy-eligible, insufficient tissue) rather than covering liquid biopsy as a first-line equivalent.
What Happens When eviCore Denies
When eviCore issues a denial, the denial letter comes from eviCore but on the payer's letterhead (or vice versa, depending on the arrangement). Read it carefully to understand whether you're appealing to eviCore or to the payer — this varies.
Peer-to-peer: Request it immediately through the eviCore portal or by calling their peer-to-peer line. The window is typically 5 business days from the denial. eviCore's medical directors are clinical — they respond well to specific clinical arguments tied to their published guidelines. Don't call to argue in general; call with the specific guideline section that supports coverage and the specific clinical facts that meet it.
First-level appeal: If peer-to-peer fails, submit a formal appeal. For most payer arrangements, the first-level appeal goes to eviCore. Include the ordering physician's letter of medical necessity, the relevant NCCN guideline pages, and any supporting peer-reviewed literature. If the denial cites a specific eviCore criterion, address it by name.
Escalation to the payer: If the eviCore appeal is upheld, the next step depends on whether the plan is fully insured (escalate to the payer's internal appeals department, then external review) or self-insured ERISA (the plan administrator governs the process). This is where you need to know your plan type.
The Most Common eviCore Denial Reasons for Oncology
- Staging insufficient — "advanced disease" not adequately documented
- Test ordered without specifying treatment decision it will guide
- Repeat NGS panel without documented clinical rationale for retesting
- Liquid biopsy requested without documentation of tissue biopsy failure
- CGP ordered for a tumor type where eviCore's pathway doesn't support it
Each of these is fixable with the right documentation at the time of submission, not after denial.
Sources
- eviCore Clinical Guidelines — evicore.com (verify current version for your specific payer)
- CMS NCD 90.2 (next-generation sequencing in cancer — referenced in eviCore's oncology criteria)
- NCCN Clinical Practice Guidelines (NCCN.org) — category designations by tumor type
- 45 CFR §147.136 (internal claims and appeals for fully insured ACA-compliant plans)
- 42 CFR §422.578 (Medicare Advantage coverage determination appeals)
- 29 USC §1133 (ERISA full and fair review for self-insured plans)